PIERI, LISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.796
EU - Europa 3.399
AS - Asia 329
OC - Oceania 14
SA - Sud America 10
AF - Africa 8
Totale 7.556
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.783
PL - Polonia 2.208
IT - Italia 333
IE - Irlanda 265
SE - Svezia 263
HK - Hong Kong 93
CN - Cina 75
CH - Svizzera 73
DE - Germania 66
FI - Finlandia 64
GB - Regno Unito 34
VN - Vietnam 34
FR - Francia 24
SG - Singapore 24
TR - Turchia 24
KR - Corea 23
JO - Giordania 20
AE - Emirati Arabi Uniti 19
UA - Ucraina 19
CA - Canada 13
AU - Australia 12
BE - Belgio 12
RU - Federazione Russa 11
ES - Italia 10
AT - Austria 9
IN - India 8
BR - Brasile 6
BY - Bielorussia 2
CO - Colombia 2
IR - Iran 2
KE - Kenya 2
NL - Olanda 2
NZ - Nuova Zelanda 2
PE - Perù 2
RO - Romania 2
SC - Seychelles 2
ZA - Sudafrica 2
AO - Angola 1
AZ - Azerbaigian 1
EE - Estonia 1
GE - Georgia 1
JP - Giappone 1
MU - Mauritius 1
QA - Qatar 1
RS - Serbia 1
TJ - Tagikistan 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 7.556
Salva come PNG Salva come JPEG
Città #
Warsaw 2.208
Fairfield 747
Ashburn 353
Woodbridge 329
Seattle 308
Chandler 279
Dublin 264
Houston 256
Wilmington 246
Cambridge 245
Ann Arbor 148
Altamura 109
Lawrence 108
Princeton 81
Bern 72
Boston 65
Florence 59
Jacksonville 52
Beijing 44
Hong Kong 38
San Diego 37
Boardman 30
Buffalo 30
Dong Ket 30
Bremen 28
New York 24
Izmir 22
Shanghai 21
Medford 20
Seoul 20
Abu Dhabi 19
Phoenix 16
Norwalk 15
Brussels 12
Kent 12
Barcelona 10
Hillsboro 10
Moscow 10
Sydney 10
Dearborn 9
Rome 9
Vienna 9
London 8
Andover 7
Parnaiba 6
Pune 6
Singapore 6
Toronto 6
Cagliari 4
Campi Bisenzio 4
Falls Church 4
Milan 4
Montreal 4
Redwood City 4
Romainville 4
West Jordan 4
Blaine 3
Bovalino 3
Laurel 3
Los Angeles 3
Noicattaro 3
Padova 3
Pesaro 3
Quartu Sant'Elena 3
Athens 2
Bari 2
Bogotá 2
Brescia 2
Brest 2
Cantagallo 2
Cecina 2
Cincinnati 2
Costa Mesa 2
Farra di Soligo 2
Gomel 2
Guangzhou 2
Huancayo 2
Kharkov 2
Kilburn 2
La Mesa 2
Munich 2
Nürnberg 2
Old Bridge 2
Pisa 2
Prato 2
Prescot 2
Pretoria 2
Reading 2
Recanati 2
Red Deer 2
Redmond 2
Salerno 2
San Mateo 2
San Miniato Basso 2
Scandicci 2
Shaoxing 2
Siena 2
Thiene 2
Turin 2
Udine 2
Totale 6.581
Salva come PNG Salva come JPEG
Nome #
Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. 282
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 248
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 246
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms 240
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 235
JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis 231
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 228
JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment. 222
Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis 215
Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis 214
Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2. 213
Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia. 209
Chronic myeloproliferative neoplasms: a collaborative approach. 208
Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients 205
Imaging studies in extramedullary hematopoiesis of the spleen 196
The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. 193
Study of new molecular alterations on Philadelphia-negative chronic myeloproliferative neoplasms 191
MPN Score 147
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 135
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 113
Mutations and prognosis in primary myelofibrosis. 105
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 105
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 102
Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis 99
Treatment options for essential thrombocythemia and polycythemia vera 97
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms 96
Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients 93
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 91
Imatinib and cardiac failure in idiopathic hypereosinophilic syndrome. 84
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. 84
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 83
Risk of second cancers in chronic myeloproliferative neoplasms. 83
Mesenchymal stem cells from JAK2(V617F) mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele. 82
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. 82
BCR-ABL1-negative chronic myeloid neoplasms: an update on management techniques 81
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 80
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. 80
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 79
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. 79
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 78
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 77
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 75
The myeloproliferative neoplasm-associated JAK2 46/1 haplotype is not overrepresented in chronic myelogenous leukemia. 73
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 72
Rationale for combination therapies in myelofibrosis 72
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 72
Concomitant occurrence of BCR-ABL and JAK2V617F mutation. 71
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. 70
Mastocitosi: approccio multidisciplinare a una patologia misconoscciuta 69
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results 67
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms An European Leukemia Net study. 66
Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene. 66
Risk of second cancers in chronic myeloproliferative neoplasms 65
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 65
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 64
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 61
Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis. 61
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. 54
The burden of symptoms in myelofibrosis: from patient-reported outcomes to health economics. 54
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 54
Masked polycythemia vera (mPV): results of an international study. 53
Prognotic Impact of Mutations in Systemic Mastocytosis 50
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. 47
Low bone mass and hypovitaminosis D in haemophilia: A single-centre study in patients with severe and moderate haemophilia A and B 47
Policitemia Vera. per conoscerla meglio. 45
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 41
Fractures needing orthopaedic surgery in haemophilic patients: long-term experience of a dedicated team at a single institution 37
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 33
Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience 21
Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis 21
Totale 7.657
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.290
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.290
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.976 161 163 58 149 238 235 223 247 197 122 155 28
2020/20211.083 103 114 42 154 66 96 55 89 101 121 73 69
2021/2022488 14 48 48 16 13 19 20 39 27 26 76 142
2022/20231.353 121 289 68 111 94 216 160 66 102 15 34 77
2023/2024519 16 46 76 22 46 72 17 110 10 31 46 27
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 7.657